Dynavax to Present at Upcoming Investor Conferences

Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX), a biopharmaceutical company focused on innovative vaccines, will present at two investor conferences in June 2024. The company will participate in the William Blair 44th Annual Growth Stock Conference on June 4 at 1:20 PM CT and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 at 4:00 PM ET. Webcasts of these presentations will be accessible on the company's website.

Positive

• Dynavax's participation in high-profile conferences like William Blair and Goldman Sachs can increase visibility and attract potential investors.
• Webcasting the presentations allows for broader access to the company's updates, potentially engaging more stakeholders.

Negative

• The PR does not provide specific financial or clinical updates, leaving investors without new substantive information regarding the company's performance or pipeline progress.
• The announcement focuses on future events rather than current achievements, which may not immediately impact the stock price.

EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June:

• William Blair 44^th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m. CT
• Goldman Sachs 45^th Annual Global Healthcare Conference on Monday, June 10 at 4:00 p.m. ET

The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

For Investors/Media:
Paul Cox
pcox@dynavax.com 
510-665-0499

Nicole Arndt
narndt@dynavax.com,  510-665-7264

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-upcoming-investor-conferences-302157153.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax present at the William Blair 44th Annual Growth Stock Conference?

Dynavax will present on June 4, 2024, at 1:20 PM CT.

When is Dynavax's presentation at the Goldman Sachs 45th Annual Global Healthcare Conference?

Dynavax's presentation is scheduled for June 10, 2024, at 4:00 PM ET.

How can I access Dynavax's investor presentations?

The presentations will be webcast and accessible through the 'Events & Presentations' page on the 'Investors' section of Dynavax's website.

What is the stock symbol for Dynavax Technologies?

The stock symbol for Dynavax Technologies is DVAX.